US 10,376,486 B2
Compositions and methods for reactivating latent viral infections
Guochun Jiang, Davis, CA (US); and Satya Dandekar, Davis, CA (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF CALIFORNIA, Oakland, CA (US)
Filed by The Regents of the University of California, Oakland, CA (US)
Filed on Feb. 7, 2017, as Appl. No. 15/426,437.
Application 15/426,437 is a continuation of application No. PCT/US2015/042716, filed on Jul. 29, 2015.
Claims priority of provisional application 62/035,333, filed on Aug. 8, 2014.
Prior Publication US 2017/0258750 A1, Sep. 14, 2017
Int. Cl. A61K 39/00 (2006.01); A61K 31/22 (2006.01); A61K 45/06 (2006.01); A61K 31/167 (2006.01); A61K 31/496 (2006.01); A61K 31/551 (2006.01); A61K 39/12 (2006.01)
CPC A61K 31/22 (2013.01) [A61K 31/167 (2013.01); A61K 31/496 (2013.01); A61K 31/551 (2013.01); A61K 39/12 (2013.01); A61K 45/06 (2013.01)] 9 Claims
OG exemplary drawing
 
1. A composition comprising ingenol-3-angelate (PEP005) and one or more additional latency reactivation agents, wherein PEP005 is present in an amount effective to synergistically enhance a therapeutic benefit of the one or more additional latency reactivation agents, wherein the therapeutic benefit comprises reactivation of a latent virus in a subject infected with the virus,
wherein the one or more additional latency reactivation agents is a positive transcription elongation factor b activator, and
wherein the virus is a human immunodeficiency virus (HIV).